200 related articles for article (PubMed ID: 12187956)
1. Immunohistochemical markers for prognosis of anaplastic astrocytomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):203-15. PubMed ID: 12187956
[TBL] [Abstract][Full Text] [Related]
2. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas.
Kirla RM; Haapasalo HK; Kalimo H; Salminen EK
Cancer; 2003 Feb; 97(3):644-8. PubMed ID: 12548606
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.
Aldape KD; Ballman K; Furth A; Buckner JC; Giannini C; Burger PC; Scheithauer BW; Jenkins RB; James CD
J Neuropathol Exp Neurol; 2004 Jul; 63(7):700-7. PubMed ID: 15290895
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M
Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.
Rodriguez EF; Scheithauer BW; Giannini C; Rynearson A; Cen L; Hoesley B; Gilmer-Flynn H; Sarkaria JN; Jenkins S; Long J; Rodriguez FJ
Acta Neuropathol; 2011 Mar; 121(3):407-20. PubMed ID: 21113787
[TBL] [Abstract][Full Text] [Related]
6. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
7. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression.
Frankel B; Longo SL; Leach C; Canute GW; Ryken TC
J Neurooncol; 2002 Aug; 59(1):27-34. PubMed ID: 12222835
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract][Full Text] [Related]
11. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
12. Expression and mutation analysis of the p53 gene in astrocytoma.
Hwang SL; Hong YR; Sy WD; Chai CY; Lin HJ; Howng SL
J Formos Med Assoc; 1999 Jan; 98(1):31-8. PubMed ID: 10063271
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors.
Khalid H; Shibata S; Kishikawa M; Yasunaga A; Iseki M; Hiura T
Cancer; 1997 Dec; 80(11):2133-40. PubMed ID: 9392336
[TBL] [Abstract][Full Text] [Related]
14. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis.
Cummings TJ; Provenzale JM; Hunter SB; Friedman AH; Klintworth GK; Bigner SH; McLendon RE
Acta Neuropathol; 2000 May; 99(5):563-70. PubMed ID: 10805102
[TBL] [Abstract][Full Text] [Related]
15. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.
Ho DM; Wong TT; Hsu CY; Ting LT; Chiang H
Cancer; 1998 Jun; 82(12):2459-66. PubMed ID: 9635540
[TBL] [Abstract][Full Text] [Related]
16. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
17. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults.
Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K
Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169
[TBL] [Abstract][Full Text] [Related]
18. Pleomorphic xanthoastrocytomas: immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute.
Korshunov A; Golanov A
J Neurooncol; 2001 Mar; 52(1):63-72. PubMed ID: 11451204
[TBL] [Abstract][Full Text] [Related]
19. Podocalyxin expression in malignant astrocytic tumors.
Hayatsu N; Kaneko MK; Mishima K; Nishikawa R; Matsutani M; Price JE; Kato Y
Biochem Biophys Res Commun; 2008 Sep; 374(2):394-8. PubMed ID: 18639524
[TBL] [Abstract][Full Text] [Related]
20. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
